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I. Introduct ion  
In  aging and  age-associated disorders like Alz- 
he imer ' s  disease, the pe r fo rmance  of various bra in  
funct ions  declines.  A d is turbance  in signal t r ansduc t ion  
be tween  b ra in  cells could under l i e  some of these age- 
re la ted or Alzhe imer ' s  d isease-re la ted deficiencies. The  
metabol i sm of the phosphoinos i t ides  plays a crucial  
role in the signal t r ansduc t ion  pathways of several 
neu ro t r ansmi t t e r s  and  neuropept ides .  The  p resen t  re- 
* Corresponding author. Fax: (+ 31) 043-671096. 
view focuses on studies deal ing with age-rela ted and  
Alzhe imer ' s  disease-rela ted changes in the metabol i sm 
of these inositol  phospholipids.  It is suggested that  
some of the changes  in the metabol i sm of phospho-  
inosit ides with age can be explained by more  general  
age-rela ted changes  in the physical proper t ies  of mem-  
branes .  Wi th  respect  to changes in phosphoinos i t ide  
metabol i sm in Alzhe imer ' s  disease, there  is growing 
evidence of specific changes  in the inositol phospho-  
lipid system which could be re la ted  to the deve lopment  
of the characterist ic  cel lular  pathology of Alzhe imer ' s  
disease. Fu tu re  research in this area is of impor tance  
in order  to de te rmine  whe ther  these changes  in phos- 
SSDI 0925 -4439(93 )E0117-T 
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phoinositide metabolism are related to the cellular 
pathology of Alzheimer 's  disease and, if so, at what 
stage in the cascade of neurochemical events leading to 
the cellular pathology of Alzheimer 's  disease these 
changes occur. 
In the twentieth century, the aging of the population 
is becoming an increasing problem in economically 
developed western countries. Aging is a problem be- 
cause it is associated with decreased functioning. The 
most obvious changes with age in humans are grey hair, 
wrinkled skin, replacement  of muscles by fat, but also a 
decline in the ability to see, hear and taste. Further- 
more, decreased motor  function, sleep, behaviour and 
cognitive functions, which probably all result from 
age-related deficiencies in the brain, are also observed. 
The effort and the expense of caring for disabled 
eldery people are enormous and still growing. More 
important,  however, is the loss of the quality of life 
caused by age-related deficits in the last decades of 
life. Aging research should therefore focus on factors 
that influence successful aging, which seems to be 
more important  than trying to prolong the maximal 
life-span of humans, by searching for the causative 
factor of aging. Biochemical research on cellular aging 
could lead to a bet ter  insight into the disturbed physio- 
logical functions associated with aging and probably to 
the prevention of many serious age-related diseases, 
such as various types of cancer, osteoporosis, athero- 
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sclerosis, and age-related brain diseases, especially de- 
menting conditions and Alzheimer's  disease, which is 
the most common type of dementia. A decline in the 
performance of some brain functions is an important 
factor in the loss of the quality of life in eldery people. 
The good functioning of the brain is based on the 
communication between neurons, which communicate 
with neighbouring cells and with more distant cells by 
means of signal-sending as well as signal-processing 
systems. One of these signal-processing systems is the 
receptor-mediated phosphoinositidc metabolism sys- 
tem. This review will focus on this system in the brain. 
A description of the phosphoinositide system and the 
interconversion of these phospholipids is given, fol- 
lowed by the changes that occur in phosphoinositide 
metabolism with age and Alzheimer's  disease. Al- 
though a great deal is known about biochemical changes 
and the cellular pathology of aging and Alzheimer's 
disease (plaques and tangle formation, for example), 
this review will focus on those aspects that could be 
related to phosphoinositide metabolism. 
II. Phosphoinositide metabolism 
A. Introduction 
The main characteristic of the brain is that its con- 
stituent cells communicate with each other and with 
other parts of the body. Much of this communication is 
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Fig. 1. Phosphoinositide hydrolysis by activated phospholipase C (PLC). A: Activation of PLC (/3-subtype) by G-protein (G) intermediated 
receptor (R) stimulation. For this role, the G-protein needs the binding of guanosine trisphosphate (GTP) which is hydrolysed in the activation 
proces of PLC-/3. B: Activation of PLC (y-subtype) by protein tyrosine kinase (PTK) intermediated receptor stimulation. Left: PTK as a part of 
the receptor (PTK-domain), Right: PTK as an independent intermediating enzyme. PLC activation results in the hydrolysis of predominantly 
phosphatidylinositol bisphosphate (PIP 2) and consequently in the release of diacylglycerol (DAG) which activates protein kinase C (PKC) 
enzymes and inositol trisphosphate (IP 3) which, together with its phosphorylation product inositol tetrakisphosphate (IP4), releases C a  2+ from 
intra- and extracellular sources. The mechanism of PLC-6 activation has not been elucidated (based on Ref. 9). 
achieved by chemical signals, such as neurotrans- 
mitters, neuropeptides and hormones, which are re- 
leased by one cell and create a reaction in another cell. 
However, most chemical signals do not enter the target 
cells, so this extracellular signal has to be transformed 
into an intracellular signal. Phosphoinositides, a class 
of phospholipids which are relatively enriched in brain 
tissue [1], play an important role in one of the path- 
ways of signal transduction through the plasma mem- 
brane. Phosphoinositides are phospholipids with the 
fully hydroxylated cyclohexane derivative inositol as 
polar head group and, predominantly, 1-stearoyl, 2- 
arachidonoyl as fatty acid tails attached to the glycerol 
backbone [2]. Phosphatidylinositol, the most abundant 
phosphoinositide, can be phosphorylated by addition of 
one or more phosphates to the inositol ring with ATP 
as phosphate donor, resulting in the formation of poly- 
phosphoinositides. The observation of Hokin and 
Hokin [3] that acetylcholine increased the incorpora- 
tion of labelled phosphate into phosphatidate and 
phosphatidylinositol in brain slices was the first report 
of a connection between signal transduction and the 
metabolism of these acidic phospholipids. Since then, 
many investigators have studied the metabolism of 
phosphoinositides in relation to receptor-mediated sig- 
nal transduction. Other (possible) functions of 
phosphoinositides have also received attention, such as 
the regulation of growth, cytoskeletal rearrangements, 
and protein anchoring to the membrane. 
B. Receptor-stimulated hydrolysis of polyphosphoinosi- 
tides 
An extracellular signal, such as a neurotransmitter 
or growth factor, initiates signal transduction through 
the membrane by binding to a specific receptor on the 
cell surface. This receptor is coupled to a 'second 
messenger-producing system' at the cytosolic side of 
the membrane, or to an ion channel. Receptors cou- 
pled to the phosphoinositide signal transduction mech- 
anism are coupled to phospholipase C (PLC), a phos- 
phoinositide-specific hydrolase. As shown in Fig. 1, this 
coupling could be achieved via an intermediate G-pro- 
tein [4,5], in analogy to the adenylate cyclase messen- 
ger system, or via tyrosine phosphorylation by a growth 
factor receptor containing a protein tyrosine kinase 
domain or an intermediate protein tyrosine kinase [6]. 
PLC activities have been purified from a wide variety 
of sources [7,8]. Comparison of amino acid sequences 
has indicated that the PLC's can be divided into three 
types (PLC-/3, PLC-y, and PLC-3) and that each type 
contains more than one subtype. Structure and regula- 
tion of activity of these PLC-subtypes has been re- 
viewed extensively [9]. G-proteins require GTP for 
stimulation of second messenger generation [4]. The 
G-proteins which belong to a large homologous family 
of trimeric proteins (a, /3, and y subunits) that are 
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always tightly associated have also been the focus of 
excellent reviews (see, e.g., Ref. 10). Besides stimula- 
tion of phosphoinositide hydrolysis by agonist-receptor 
interactions, inhibition of hydrolysis has also been ob- 
served after agonist-receptor interactions [11]. 
Because inositol trisphosphate (I(1,4,5)P 3) is the first 
inositol metabolite which accumulates after receptor 
activation [12,13], the main candidate for receptor- 
stimulated hydrolysis is the twice phosphorylated phos- 
phatidylinositol 4,5-bisphosphate (PI(4,5)P e) [14], 
formed by the consecutive phosphorylation of phospha- 
tidylinositol (PI) to phosphatidylinositol 4-phosphate 
(PI(4)P) by PI 4-kinase and of PI(4)P to PI(4,5)P 2 by 
PI(4)P 5-kinase [15,16]. However, the receptor-stimu- 
lated hydrolysis of PI and PIP has also been suggested 
[17,18], resulting in the release of inositol monophos- 
phate or diphosphate, respectively. Only a small por- 
tion of the inositol lipid pool is involved in signalling 
[19-21] and appears to be confined to the plasma 
membrane [22]. The hydrolysis of PI(4,5)P 2 results in 
the release of the second messengers inositol-l,4,5-tris- 
phosphate (I(1,4,5)P 3) and diacylglycerol (DAG) [23]. 
Water-soluble I(1,4,5)P 3 enters the cytosolic com- 
partment and either binds to an I(1,4,5)P 3 receptor or 
is metabolized [24]. Binding to the I(1,4,5)P 3 receptor 
results in the release of Ca 2+ from intracellular stores 
[25], probably the endoplasmic reticulum [26], via the 
opening of a Ca 2+ channel [27]. This Ca 2+ release 
from intracellular stores is followed by the entry of 
extracellular calcium [18]. It has been suggested that 
the entry of extracellular calcium is initiated by inositol 
tetrakisphosphate (I(1,3,4,5)P 4) [28,29]. However, both 
IP 3 and IP 4 are required for a full response [29,30], in 
which I(1,4,5)P 3 causes a transient rise in Ca 2+ and the 
presence of I(1,3,4,5)P 4 leads to a sustained increase in 
Ca 2+ levels, probably by replenishing the I(1,4,5)P 3 
sensitive Ca 2+ pool [31]. The complex metabolism of 
inositol phosphates has been reviewed recently [30,32]. 
Changes in the concentration of calcium play a central 
role in the regulation of various signalling and regula- 
tory factors (such as several protein kinases and phos- 
pholipases) essential for neuronal functioning [33]. 
Besides IP 3 as CaZ+-mobilizing second messenger, 
DAG is also released by the receptor-stimulated hydro- 
lysis of PIP 2 [23]. DAG remains in the plasma mem- 
brane and activates protein kinase C (PKC) in the 
presence of phosphatidylserine and calcium [34]. DAG 
increases the affinity of PKC for Ca 2+, so that maximal 
PKC activity is possible at basal cytosolic Ca 2 + concen- 
trations [35]. However, several new members of the 
PKC family, whose activities are dependent on D A G /  
phospholipid but independent of Ca 2+, have been 
identified. Recently, the various PKC isoenzymes and 
their regulation mechanism have been reviewed by 
Azzi et al. [36]. The level of DAG is a function of its 
production from phosphoinositides but also other 
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phospholipids like phosphatidylcholine, and its phos- 
phorylation to PA or its degradation to its building 
blocks [37]. Upon cell stimulation, DAG is rapidly 
converted by diacylglycerol kinase to phosphatidic acid 
(PA) [38], which could have two functions: first, to 
initiate the resynthesis of the phosphoinositides, and 
second, to control the concentration of the second 
messenger DAG, thus acting as a regulator of PKC 
[39]. Although PA formed after DAG phosphorylation 
could be 'just' an intermediate in the resynthesis of 
phosphoinositides as described above, there are also 
indications that PA may directly mediate the inward 
movement of Ca 2÷ after activation of membrane re- 
ceptors [40]. DAG breakdown is catalysed by DAG 
lipase resulting in the liberation of arachidonic acid 
(AA). The DAG phosphorylation product PA can be 
broken down to release AA by the activation of spe- 
cific phospholipase A 2 [41,42]. 
The IP 3 branch and the DAG branch of the phos- 
phoinositide signal cascade appear to act synergistically 
to phosphorylate proteins, the former by elevating Ca 2 ÷ 
concentrations resulting in an increased protein phos- 
phorylation, and the latter by activating PKC [18,37]. 
The protein kinases regulate many other enzymes, ion 
channels, etc., by phosphorylation, ultimately resulting 
in a biological response [43]. 
Receptor-stimulated inositol phospholipid hydroly- 
sis or the so-called 'PI effect' is found in various tissues 
of several species (listed in [23,37,44]), including, of 
course, the central nervous system (CNS). In their 
extensive review Fisher et al. [32] listed the receptors 
present on neurons and /o r  glia known to be linked to 
phosphoinositide turnover. They distinguish two groups 
of receptors: Category 1 receptors, which elicit a robust 
increase in inositol phospholipid turnover in tissue 
preparations of both the CNS and neurotumour cells, 
including muscarinic cholinergic, adrenergic, histamin- 
ergic, serotonergic, glutamatergic, and endothelin re- 
ceptors; and Category 2 receptors, which elicit only a 
small increase in inositol phospholipid turnover in 
CNS-derived preparations, including purinergic, nerve 
growth factor, prostaglandin, bradykinin, vasopressin, 
oxytocin, thyrotropin-releasing hormone, and other re- 
ceptors [32]. 
C. D-3 phosphorylated inositol phospholipids 
The metabolism of inositol phospholipids has re- 
cently become more complex with the discovery of D-3 
phosphorylated inositol phospholipids (Fig. 2). Whit- 
man et al. [45] divided the PI kinases into two different 
types. Type 2 PI kinase appears to be a PI 4-kinase and 
is involved in the production of PI-4-P and ultimately 
PI-4,5-P2, used for receptor-stimulated phosphoinosi- 
tide hydrolysis [15]. Type 1 PI kinase appears to be a PI 
3-kinase [46]. The D-3 phosphorylation of the novel 
inositol phospholipid (PI(3)P) was also shown by 
P l ~ .  N PI-4-P 
PI-3-P 
~{ Z>" PI-4,5-P2 
• ~1~ PI-3,4-P2 -,K--~.~ PI-3,4,5-P3 
" " . . .  
PI-3,5-P2 
Fig. 2. Schematic diagram of phosphoinositide phosphorylation and 
dephosphorylation pathways. The 'conventional'  pathway is shown 
above (PI ~ PI-4P ~ PI-4,5P2). PI 3-kinase phosphorylates PI, PI-4-P 
and PI4,5-P 2 at the D-3 position of the inositol ring. After receptor 
stimulation of PI 3-kinase activity, PI-4,5-P 2 seems the preferred 
substrate of PI 3-kinase [50]. The existence of a PI-3-P 5-kinase 
activity is still controversial (based on Refs. 15,63). 
Stephens et al. [47]. Besides PI(3)P, PI(3,4)P 2 (with 
PI(4)P as substrate) and PI(3,4,5)P 3 (with PI(4,5)P 2 as 
substrate) have also been detected [48]. After growth 
factor receptor stimulation, PI(3,4)P 2 and PI(3,4,5)P 3 
are substantially raised [49], although Hawkins et al. 
[50] postulate that PI(3,4,5)P 3 is the primary candidate 
for the role of output signal and that PI(3,4)P2 is 'just' 
a dephosphorylation product of PI(3,4,5)P 3. An inositol 
tetrakisphosphate-containing inositol phospholipid was 
also found by Traynor-Kaplan et al. [51] and Vadnal 
and Parthasarathy [52], who suggested that PIP 3 could 
be the parent compound of IP 4. However, polyphos- 
phoinositides phosphorylated in the D-3 position are 
poor substrates for phospholipase C from rat liver and 
bovine brain [53]. Probably just one enzyme is responsi- 
ble for the production of these D-3 phosphorylated 
compounds, as purified type 1 PI 3-kinase can use PI, 
PI(4)P and PI(4,5)P 2 as substrate with almost equal 
kinetic characteristics [54], although Cunningham et al. 
[55] also report the phosphorylation of PI(3)P to 
PI(3,4)P 2 and PI(3,4)P 2 to PI(3,4,5)P 3. 
The main feature of this enzyme activity or these 
enzyme activities is its (their) association with activated 
protein tyrosine kinases of growth factor receptors and 
oncogene products. These protein tyrosine kinases in- 
clude pp60v-src, the polyoma middle T antigen/ 
pp60c-src complex, the PDGF receptor, the CSF-1 
receptor, the insulin receptor, and p68v-ros, the trans- 
forming protein of the avian sarcoma virus UR2, as 
listed by Cantley et al. [56]. Therefore, PI 3-kinase 
seems to be involved in cell transformation and cell 
divison. This notion is strengthened by the results of 
mutation studies in which a loss of PI 3-kinase associa- 
tion coincides with a loss of the potency to transform 
cells [57-62]. However, cells in a terminally differenti- 
ated form, such as neutrophils and platelets, also pro- 
duce D-3 phosphorylated phosphoinositides as a result 
of cell activation by agonists (listed in Ref. 63). Auger 
and Cantley [63] suggest that the novel polyphospho- 
inositides are involved in cytoskeletal reorganization 
because the effects found in neutrophils and platelets, 
as mentioned above, coincide with cytoskeletal changes, 
and a lack of association of PI 3-kinase appears to 
correlate with the lack of actin reorganization and 
mitogenic signals. In addition to this, some reports 
suggest a direct link between phosphoinositides and 
cytoskeletal components [64-66]. 
D. Glycosylated inositol phospholipids 
Membrane-bound proteins can be attached to the 
membrane in various ways [67]. Until recently, this 
attachment was believed to be non-covalent in nature, 
by hydrophobic interaction of the protein with the 
membrane bilayer. However, in the last decade it has 
become clear that various membrane-bound proteins 
contain covalently bound lipid, in some cases a glyco- 
sylated phosphatidylinositol moiety [67]. The proteins 
utilizing glycosyl-phosphatidylinositol (GPI) as a mem- 
brane anchor are listed in reviews by Low [68] and 
Lisanti et al. [69]. Lisanti et al. [69] discuss the possible 
functions of this strange and complicated way of mem- 
brane attachment, and suggest functions in the cellular 
distribution of proteins, the lateral mobility of proteins, 
the exclusion of anchored proteins from clathrin-coated 
pits, and/or ,  the regulation of the release of proteins 
[30,69]. 
In several cell types, a GPI has been described 
which shares the core structure of Plglucosamine and 
contains additional monosacharides, but which lacks 
ethanolamine and is not attached to protein [70]. It 
seems that these non-protein-bound GPIs, which are 
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supposed to be located on the cytoplasmic side of the 
plasma membrane, can be hydrolysed by an insulin- 
stimulated and phospholipase-mediated mechanism, 
resulting in the release of a novel second messenger, 
the inositol-glycan, and DAG [71,72]. This novel sec- 
ond messenger affects particular enzymes in vitro, but 
its mechanism of action is not known [73]. 
IlL Phosphoinositide metabolism and aging 
Phosphoinositide metabolism has many different as- 
pects that are important for the functioning of cells, as 
we have seen above. According to Magnoni et al. [43], 
there is considerable evidence that the aging process 
affects this signalling cascade at different levels, from 
receptor availability to stimulation of second and third 
(protein phosphorylation) messengers. An overview of 
current knowledge of these different levels of the inosi- 
tide signalling cascade in relation to aging (Table 1) is 
given below. 
A. Phospholipids and aging 
Phosphoinositides are normal components of the 
plasma membrane as mentioned earlier. The most re- 
markable change in the plasma membrane with age is 
the increase in the cholesterol/phospholipid ratio 
[74,75]. This increase in cholesterol/phospholipid ratio 
appears to correlate with the microviscosity of the 
membranes involved [76,77], which means that mere- 
TABLE I 
Phosphoinositide metabolism and aging 
Parameter  of  phosphoinosit ide metabolism Tissue Change with age Ref. 
Lipid myo-inositol concentrat ions human  anterior temporal  cortex J, 82 
Endogenous  phospholipid phosphorylation: (rat frontal-, parietal-, entorhinal- cortex, hippocampus,  
P A  formation 
PIP 2 formation 
PIP formation 
PI kinase activity 
PIP kinase activity 
Basal inositol phospholipid labeling and hydrolysis 
Stimulated PLC activity: carbachol 
carbachol 
carbachol 
noradrenaline 
oxotremorine-M 
Stimulated IP 4 formation: 
IP 3 receptor density 
IP 3 induced Ca 2+ release 
phenylepherine 
phenylepher ine 
SKF38393 
carbachol 
striatum, thalamus,  hypothalamus) 
rat hippocampus,  frontal cortex, striatum, thalamus,  
hypothalamus ~ 95, 96 
frontal cortex, hypothalamus ~ 95, 96 
all structures - 95, 96 
human  temporal  cortex $ 97 
human  temporal  cortex - 97 
rat striatum, hippocampus,  frontal cortex $ 93 
rat hippocampal slices 1" 85 
rat cerebral cortex slices T 86, 87 
rat cortex, s t r ia tum $ 87, 90 
rat cerebral cortex slices ~' 86 
rat cerebral cortex, striatum, hippo- 
campus,  thalamus,  hypothalamus,  cerebellum - 88 
rat thalamus and cerebral cortex ,L 89 
rat h ippocampus - 89 
rat striatum, hippocampus,  frontal cortex J, 93 
rat cerebral cortex slices ,[ 93 
rat cerebellum J, 84 
rat cerebral cortex - 84 
rat cerebral cortex microsomes J, 188 
parotid cells $ 106 
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brane fluidity decreases with age. The effects of changes 
in membrane fluidity on integral membrane proteins 
are discussed later. Other age-associated changes in 
plasma membrane components include an increased 
turnover of phospholipids in rat brain [78], an in- 
creased methylation of phosphatidylethanolamine by 
phospholipid methyltransferase I, although phospho- 
lipid methyl transferase II is unaffected in rat brain 
[79], a decreased synthesis of phosphatidylethanol- 
amine and phosphatidylcholine, which seems to involve 
mostly neuronal rather than glial cells [80], a rapid loss 
of membrane lipids after 90 years of age in humans 
[81], and a decrease in lipid-myoinositol concentrations 
in human anterior temporal cortex (Brodman area 38) 
[82]. Biochemical changes in the membranes of cyto- 
plasmic organelles of aging cells are mostly similar to 
those occurring in the plasma membrane [75]. How- 
ever, lipid peroxidation is increased in the mitochon- 
drial membranes of aged animals [83]. Lipofuscins, or 
age pigments, which are precipitated in lysosomes, are 
derived from the peroxidation of subcellular mem- 
branes containing polyunsaturated lipids (see Ref. 75 
and refs. therein). 
B. Receptor-mediated phosphoinositide hydrolysis and 
aging 
Receptor-mediated phosphoinositide hydrolysis is 
one of the signal transduction systems by which a cell 
transforms an extracellular signal into an intracellular 
response via the release of intracellular messengers. A 
disruption of the phosphoinositide second messenger 
systems with age could be related to the impairment of 
neurological responsiveness and the behavioural 
deficits observed with aging [84]. The carbachol-stimu- 
lated release of inositol phosphates has been recently 
found to increase with age in hippocampal slices [85] 
and in cerebral cortex slices [86,87], and the noradrena- 
line-stimulated release of inositol phosphates has also 
been found to increase with age in cerebral cortex 
slices [86]. These effects occur in the absence of a 
change in the number of binding sites [85,87]. How- 
ever, other investigators have reported no change in 
receptor-mediated inositol phosphate release (mus- 
carinic receptor [88]). A decrease in inositol phosphate 
release was even reported after stimulation of cortical 
a-l-adrenergic receptors [89], cortical muscarinic re- 
ceptors [90] and striatal muscarinic receptors [87]. Be- 
sides age-related effects on agonist-stimulated inositol 
trisphosphate release, carbachol-stimulated I(1,3,4,5)P 4 
formation was reduced by 44% in old rat cerebral 
cortex slices [91]. Aging of the rat brain could be 
associated with alterations in the basal turnover of the 
inositol cycle [92]. Undie and Friedman [93] observed 
that basal inositol phospholipid labeling and hydrolysis 
are decreased in the aging rat brain. These age-related 
changes were reversed by diet restriction which sug- 
gests that altered phospholipid content or metabolism 
may be responsible [93]. This notion was strengthened 
by the results of a study in which synaptosomal plasma 
membranes were phosphorylated with endogenous 
phospholipids as substrates. Endogenous PA formation 
decreased with age in whole brain, and PIP~ formati(m 
decreased with age in the frontal cortex [94--96]. These 
effects were probably due to endogenous substrate 
availability because measurement of specific kinase 
activities, after solubilization of the enzymes and addi- 
tion of exogenous substrates, revealed no, or only mi- 
nor, age-related changes in rat brain cortex (Bothmer 
et al., submitted). In contrast to this latter finding, 
comparable solubilized protein fractions from human 
tissue (cerebral cortex) showed an age-related decline 
in PI kinase activity, whereas PIP kinase activity showed 
no age-related change [97]. 
Age-related changes in receptor-stimulated inositol 
phosphate release may be dependent upon the recep- 
tor-effector coupling or a change in the stoichiometry 
of the receptor-G-protein-phospholipase C interaction 
[90]. This latter idea is supported by the finding that in 
cultured rat heart myocytes, the inhibition of cAMP 
accumulation through Gi-proteins is lost with age [98] 
and that the decrease in adenylate cyclase activity in 
the submandibular salivary glands of aged rats seems 
partly due to changes in the availability of G-proteins 
[99]. An age-related uncoupling of the receptor-G-pro- 
tein-phospholipase C interaction could be caused by 
age-related changes in membrane properties, such as 
membrane fluidity, as described before [74,100]. Un- 
coupling of the 'muscarinic receptor/cAMP inhibition' 
interaction in aged rat heart myocytes in culture is 
restored by phosphatidylcholine-liposome treatment 
[98]. Membrane viscosity also appears to correlate with 
al-adrenergic signal transduction in the cerebral cortex 
of aged rats [101] and, in addition, chronic treatment 
with phosphatidylserine restores muscarinic cholinergic 
receptor deficits in the brains of aged mice [102]. The 
effect of membrane fluidity on the 'receptor-G-pro- 
tein-second messenger production' interaction is ac- 
companied by an effect of membrane fluidity on recep- 
tor binding with age [100,103]; however, receptor bind- 
ing as a function of age will not be discussed here. 
C. Inositol phosphate action, the cytoskeleton and aging 
Age-related changes in the level of inositol phos- 
phates released after receptor stimulation have been 
described. Inositol trisphosphate releases calcium from 
intracellular stores, and cytosolic free calcium is an 
important second messenger controlling many aspects 
of neuronal function and excitability. However, the 
cytosolic calcium concentration has to be normalized 
by calcium extrusion at the plasma membrane (Na/Ca 
exchanger and Ca2+-ATPase) and by calcium seques- 
tration in intracellular organelles (mitochondria and 
endoplasmic reticulum). Calcium homeostasis and its 
changes with age are reviewed by Gibson and Peterson 
[104]. The action of inositol polyphosphates in releas- 
ing Ca 2÷ from intracellular stores is thought to be 
affected by the aging process [105], as the density of 
inositol trisphosphate receptors is decreased in the 
cerebellum, but not in the cerebral cortex of old rats 
[84]. Furthermore, the amount of calcium released 
from microsomes by inositol trisphosphate decreases 
with age in rat brain [188] and parotid cells [106], and 
resting levels of cytosolic free calcium are decreased in 
fibroblasts from aged humans [107]. 
The cytoskeleton plays an important role in recep- 
tor-mediated phosphoinositide metabolism by keeping 
the receptors, G-proteins and enzymes involved to- 
gether, as receptors are directly linked to the cyto- 
skeleton [75], as are inositol phospholipid kinases, dia- 
cylglycerol kinase and phospholipase C [108,109]. Fur- 
thermore, D-3 phosphorylated inositol phospholipids 
seem to be involved in the processes of cytoskeleton 
turnover. In aging, there is a disequilibrium between 
polymer and monomer forms of tubulin and a disorga- 
nization of the cytoskeleton [75]. The microtubule-as- 
sociated proteins MAP1 and MAP2, which contribute 
significantly to the polymerization of brain tubulin, are 
degraded to a greater extent in aged rat brain because 
of an increased proteolytic activity of cathepsin D 
[110]. The age-related changes in the cytoskeleton are 
probably partially due to age-related changes in Ca 2÷ 
homeostasis, as calcium/calmodulin-dependent kinase 
II is an important regulator of the neuronal cyto- 
skeleton [111]. Because phosphoinositide metabolism is 
a regulator of Ca 2+ homeostasis, age-related changes 
in the cytoskeleton could be related to age-related 
changes in phosphoinositide metabolism. 
D. Protein kinases and aging 
Several types of protein kinases are activated as a 
result of receptor-stimulated phosphoinositide hydroly- 
sis. For example, calcium/calmodulin-dependent pro- 
tein kinase is activated by the elevated cytosolic cal- 
cium concentrations as a result of the action of inositol 
trisphosphate, and protein kinase C is activated by 
diacylglycerol, the second messenger which is released 
simultaneously with inositol trisphosphate. PKC is re- 
ported to be modified during aging in various cerebral 
areas, as a result of either enzyme activity or substrate 
availability [43]. How aging affects the activity of cal- 
cium/calmodulin-dependent protein kinase needs to 
be explored. 
In Sprague-Dawley rats, phorbol ester binding and 
PKC activity are reduced with age in the cortex, en- 
hanced in the hippocampus and unmodified in the 
cerebellum [112]. At the level of the hypothalamus, 
PKC activity appears to decrease with age in contrast 
to pituitary PKC, which shows an age-related up-regu- 
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lation [113]. Fisher 344 rats also show an age-related 
reduction in PKC activity in the cortex, but no changes 
in the hippocampus and the cerebellum [114]. The 
age-related impairment in PKC activity in rat brain 
cortex may affect transmitter release, because antibod- 
ies against the PKC substrate B-50 inhibit noradrena- 
line release, and, furthermore, B-50 phosphorylation is 
increased by depolarization [115]. In addition, the stim- 
ulatory action of activated PKC on serotonin release in 
the cortex of adult rats changes to an inhibition with 
age [114]. The age-related modifications of the PKC 
pathway in different cerebral areas and rat strains are 
reviewed by Magnoni et al. [43]. Hershkowitz et al. 
[103] have shown that a decrease in lipid fluidity, which 
occurs with age, results in a modulation of protein 
phosphorylation in synaptic membranes. 
IV. Phosphoinositide metabolism and Alzheimer's dis- 
ease 
A. Introduction 
Aging as defined in part 1 also includes age-associ- 
ated brain disorders such as dementia. About 55-75% 
of the cases of adult-onset dementia are of the 
Alzheimer type. Alzheimer's disease (AD) generally 
occurs at ages greater than 65 years, but in a small 
number of cases it strikes people in their forties and 
fifties [116]. The diagnosis of AD is very difficult espe- 
cially in the early stages, because the symptoms overlap 
with those seen in normal aging [117]. There is no 
certain means of diagnosis other than brain biopsy 
[118]. AD is characterized clinically by a progressive 
deterioration of memory, personality and intellect [119]. 
In addition to the clinical syndrome, AD is charac- 
terized histochemically by the occurrence of neuritic 
plaques and neurofibrillary tangles. Plaques consist of 
a central core of amyloid fibrils surrounded by dys- 
trophic neurites together with reactive microglia and 
astrocytes [120]. With increasing severity of dementia, 
these mature plaques are formed out of diffuse plaques 
which do not have a central core and are already 
present in very mildly demented peoples [121]. The 
sequence of /3/A4, which is the major component of 
plaque cores, is encoded by a gene for the amyloid 
precursor protein (APP) [122]. APP spans the mem- 
brane once and has a large extracellular amino-termi- 
nal domain with a short carboxy-terminal cytoplasmic 
tail [122]. The /3/A4 sequence in APP begins close to 
the membrane on the extracellular side and ends part- 
way through the putative transmembrane region [120]. 
Under normal conditions, the extracellular part can be 
released by enzyme action in the /3/A4 region 
[123,124], resulting in the release of a soluble APP. In 
AD the [3/A4 sequence is released intact, which means 
that there has to be an extracellular cleavage site and 
another site in the transmembrane region of APP. How 
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an enzyme gains access to that t ransmembranc region 
is still unsolved. Several investigators hypothesize the 
release of [3/A4 to be the primary cause of AD, and 
think that all other aspects of AD are secondary events. 
The fact that a mutation of the APP gene, as in 
familial AD, can give rise to all of the neuropathologi- 
cal hallmarks of AD without there being any other 
defect strongly suggests that amyloid mismetabolism 
and deposition is the seminal event in the pathogenesis 
of all cases of AD [120,125]. According to this hypothe- 
sis neurofibrillary tangles would develop secondary to 
the deposition of [3/A4. However, Price et al. [121] 
have shown that the first development of tangles and 
plaques occurs in different parts of the brain. The 
composition of these neurofibrillary tangles are dis- 
cussed in Section IV.E., The cytoskeleton and Alz- 
heimer 's  disease: neurofibrillary tangles. 
According to Selkoe [125], the difference between 
normal brain aging and AD is quantitative rather  than 
qualitative, because normal non-demented subjects also 
develop at least a few senile plaques and neurofibril- 
lary tangles, particularly in the hippocampus and other 
brain regions important for memory. Tangles appear  
with age in the olfactory nucleus, the parahippocampal  
gyrus and the hippocampus,  but are rare in the neuro- 
cortex except in demented persons. Conversely, plaques 
may develop first in the neocortex, which implies that 
tangles and plaques first develop in different parts of 
the brain [121]. However,  the aetiology and pathogene- 
sis of AD are still not known. Therefore,  because 
phosphoinositides are involved in various important 
cell functions, this review emphasizes the fact that AD 
is also characterized by changes in the metabolism of 
phospholipids and of phosphoinositides (Table II) in 
particular. 
B. Phospholipids and Alzheimer's disease 
Phospholipids are the main components  of the 
membrane,  and the condition of this membrane  can 
TABLE II 
Phosphoinositide metabolism and Alzheimer's disease 
influence the proteins attached to it, for instance re- 
ceptors, G-proteins and enzymes, as mentioned above. 
3~p NMR studies have demonstrated that there are 
increased levels of phosphomonoesters,  possibly as the 
result of higher PLC activities, early in the course of 
A D  and increased levels of phosphodiesters as the 
disease progresses [126]. The levels of phosphomo- 
noesters are inversely correlated with the number of 
senile plaques, whereas the levels of phosphodiesters 
are positively correlated with the numbers of senile 
plaques [127]. These and additional findings resulted in 
the hypothesis that the earliest molecular /metabol ic  
changes in AD result in elevated levels of phosphomo- 
noesters in the neocortex and allocortex, followed by a 
cortical and subcortical elevation of phosphodiesters 
later in the course of the disease, which reflects cellu- 
lar degenerat ion and death (see Ref. 126 and refs. 
therein). A physiologically relevant action of L-phos- 
phoserine, one of the phosphomonoesters  elevated in 
AD, has been suggested because whole brain concen- 
trations may reach over 1 mM in AD and 1.-phospho- 
serine has close structural similarities to ~:glutamate, 
which means that it could interact with the glutamate 
receptor [ 128]. 
Furthermore,  there appears  to be an increased 
degradation of phospholipids in AD brain (frontal, 
parietal and primary auditory cortex) as phosphatidyl- 
choline and phosphatidylethanolamine levels and the 
levels of their precursors choline and ethanolamine are 
decreased in contrast to the levels of their deacylation 
products, which are increased [129]. These phospho- 
lipid abnormalities appear  not to be an epiphe- 
nomenon of neurodegenerat ion but may be specific for 
the pathomechanism of AD [129]. In the anterior tem- 
poral cortex of AD brains, PI levels are significantly 
lower than in the same area of age-matched control 
brains [130]. Stokes and Hawthorne [130] have also 
reported that PIP and PIP 2 levels tend to decrease in 
AD; however, these data may have been affected by 
Parameter of phosphoinositide metabolism Tissue Change in AD Ref. 
PI levels 
PIP and PIP 2 levels 
PI kinase activity 
PIP kinase activity 
'Type 1' PI kinase activity 
PI and PIP kinase activity 
ml-muscarinic receptor-Gprotein coupling 
Gprotein a-subunit levels 
Abberant accumulation of PLC-6 
Abberant accumulation of PLC-fl, -A 1 and -A 2 
Basal PLC activity 
Stimulated PLC activity: 5-HT 
bradykinin 
Number of IP3 binding sites 
cerebral anterior temporal cortex J, 130 
cerebral anterior temporal cortex J, (tendency) 130 
frontal, precentral, temporal and parietal cortex J, 148 
frontal, precentral, temporal and parietal cortex - 148 
temporal cortex ~ 149, 
blood platelets of AD donors - 152, 
temporal cortex - 143 
frontal cortex, hippocampus, cerebellum - 144 
temporal cortex, hippocampus 1" 145 
temporal cortex, hippocampus 145 
frontal cortex, hippocampus 147 
frontal and parietal cortex 141 
fibroblasts of AD donors 146 
temporal cortex, hippocampus $ 154 
150 
153 
the long and variable post-mortem delay, because poly- 
phosphoinositides are rapidly degraded post-mortem 
[131]. The composition of brain membranes is thus 
altered in AD, and this probably results in functionally 
significant alterations in the biophysical properties of 
brain cell membranes [132]. 
C. Receptor-mediated phosphoinositide hydrolysis and 
Alzheimer' s disease 
As in aging, the different levels of the inositide 
signalling cascade are or could be involved in AD. 
Fowler et al. [133] hypothesized that there is a decline 
in the functional integrity of receptor-mediated signal 
transduction mechanisms, such as cAMP release and 
the inositol phosphate/diacylglycerol release systems, 
in AD, although most studies of receptor function in 
AD have considered only the receptor recognition site 
[134]. Interestingly, several of the neurotransmitter sys- 
tems affected in AD, such as the cholinergic, seroton- 
ergic and noradrenergic systems, are coupled to these 
effector systems [133]. However, receptor binding and 
receptor number have been reviewed extensively [134- 
136] and will not be discussed. 
'Receptor-G-protein-second messenger producer' 
coupling in AD brain membranes had not been studied 
until recently. Stimulated adenylate cyclase activity ap- 
pears to be reduced in the superior temporal cortex 
and hippocampus of AD brains [137,138], although in 
another study stimulated adenylate cyclase activity in 
frontal cortex, hippocampus, caudate nucleus and cere- 
bellum preparations was unaffected [139]. In addition, 
Cowburn et al. [140] report a widespread impairment 
of G-protein-stimulated adenylate cyclase activity in 
the frontal cortex of AD brains. This impairment oc- 
curs in the absence of an altered enzyme catalytic 
activity and is unlikely to be the result of non-disease- 
related factors associated with the nature of the termi- 
nal illness of individuals. The coupling of the 5- 
hydroxytryptamine-lA receptor, which has been re- 
ported to be coupled to both adenylate cyclase and 
phospholipase C, to G-proteins appears to be intact in 
frontal and parietal cortices of AD brain [141]. The 
Gi-protein-mediated inhibition of adenylate cyclase ac- 
tivity is also not impaired in four regions of AD brain 
(temporal cortex, frontal cortex, angular gyrus and 
cerebellum) [142]. In addition, the coupling of M1- 
muscarinic receptors, which preferentially activate 
phospholipase C, to G-proteins in the temporal cortex 
of AD brain is also unaffected [143]. According to 
McLaughlin et al. [144], changes in the amount of 
G-protein a-subunits are not a feature of the frontal 
cortex, hippocampus and cerebellum of AD brain, in 
contrast to the aberrant accumulation of phospholipase 
C-6 in the temporal cortex and hippocampus of AD 
brains. This accumulation of phospholipase C-3 but 
not of other PLC subtypes is suggested to be a crucial 
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event that may ultimately contribute to the formation 
of paired helical filaments [145]. Because there is very 
little tritium labelling of polyphosphoinositides after 
incubation of autopsy samples, receptor-mediated inos- 
itol phospholipid breakdown in postmortem material is 
difficult to measure [133]. The bradykinin-induced for- 
mation of IP 3 and IP 2 was measured in fibroblasts from 
AD donors, but did not differ from that of normal aged 
donors [146]. The enzyme activity of PLC does not 
appear to be affected in the frontal cortex and hip- 
pocampus of AD brains [147], thus a possible change in 
inositol phosphate release can only be caused at the 
receptor-G-protein-PLC coupling level, at the level of 
receptor density, or at the level of PIP 2 supply (activity 
of PI and PIP kinases). In cytosolic preparations of 
brain cortex (frontal, precentral, temporal and parietal 
cortices) of AD patients, PI kinase activity appears to 
be decreased compared with that of age-matched con- 
trol subjects, whereas PIP kinase activity was not af- 
fected [148]. Because AD patients with an 'age of first 
symptoms' above 75 years had a higher PI kinase 
activity in the temporal cortex than AD patients with 
an 'age of first symptoms' below 75 years, PI kinase 
activity could possibly be used to divide AD patients 
into subgroups characterized by the age of onset of the 
disease [97]. The greatest decline in PI kinase activity 
in the cortex of AD brain was found in the cytosolic 
fractions, in contrast to the PI kinase activity in inte- 
gral membrane protein fractions. Cytosolic PI kinase 
activity was inhibited by Triton X-100 but was rela- 
tively insensitive to adenosine [149], which are features 
characteristic of type 1 PI kinase or PI 3-kinase [15]. 
These results suggest that just one type of PI kinase is 
affected in the cortex of AD brains, namely type 1 PI 
kinase which seems to be involved in the regulation of 
the turnover of the cytoskeleton [150]. Therefore, a 
decrease in the activity of this type of PI kinase could 
be closely related to the cellular pathology of AD, as 
neurofibrillary tangles are partially composed of incor- 
rectly metabolized cytoskeletal components. Despite 
the indication that, firstly, disease-specific abnormali- 
ties in the brain, such as those occurring in diseases 
like Parkinson's disease, Huntington's disease and de- 
pression, can be reflected in blood platelets [151], and 
secondly, PI kinase activity is substantially decreased in 
the cortex of AD brains, PI kinase activity in platelets 
from AD patients was not different from that of con- 
trol platelets [152,153]. 
D. Calcium release, protein phosphorylation and 
Alzheimer ' s disease 
Because phosphoinositide-mediated signal transduc- 
tion results in changes in calcium homeostasis and 
protein kinase activities, this part of the review deals 
with age- and Alzheimer's disease-related changes in 
these aspects. 
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It is not known whether the release of inosito[ 
phosphates is altered in AD brain, mainly because of 
the technical problems mentioned above. However, the 
number of IP 3 binding sites essential for calcium re- 
lease in the temporal cortex and hippocampus is 
severely reduced (50-70% loss) in AD brains [154]. 
The same technical problems for the measurement of 
inositol phosphate release also exist for the measure- 
ment of calcium concentrations and fluxes in AD 
brains. Cytosolic free calcium and cell spreading of 
calcium is decreased in fibroblasts from AD donors 
[107]. Furthermore, Na+/Ca  2+ exchange activity is 
increased in the frontal cortex, temporal cortex and 
hippocampus of AD brain tissue, which is interpreted 
as indicating that neurons surviving in brain regions 
suffering the greatest degeneration as a result of AD 
have increased Na+/Ca  2+ exchange activity [155]. Ac- 
cording to Mattson et al. [156], a disturbed calcium 
homeostasis, resulting in higher intracellular calcium 
concentrations, together with a disturbed inositol phos- 
pholipid metabolism, could be involved in neurofibril- 
lary degeneration through the activation of protein 
kinases, because tau, a microtubule-associated protein, 
is abnormally phosphorylated in paired helical fila- 
ments. 
Elevated calcium levels and activation of PKC both 
induce an increased paired helical filament-tau im- 
munoreactivity in neuronal cell cultures, and addition 
of the PKC inhibitor H-7 blocks the increase in im- 
mune reactivity [156]. Furthermore, PKC is able to 
phosphorylate tau [157,158] as well as neurofilament 
proteins [159,160]. 
Protein phosphorylation and the occurrence of se- 
nile plaques also seem to be related. A synthetic pep- 
tide corresponding to a region of amyloid precursor 
protein is phosphorylated by PKC, suggesting that amy- 
loid precursor protein could be a physiological sub- 
strate of PKC [161]. Furthermore, PKC immunoreactiv- 
ity is present in mature plaques [162,163], whereas 
diffuse plaques only show immunoreactivity for the 
PKC subtype/3II. This PKC/3II subtype is probably an 
early biochemical marker of AD, because diffuse 
plaques do not show immunoreactivity for senile plaque 
markers such as casein kinase II, tau or paired helical 
filaments [164]. Interestingly, this /3II PKC subtype is 
strongly associated with the cytoskeleton and is proba- 
bly responsible for the phosphorylation of the growth- 
associated GAP43 or B-50 protein [165]. In the frontal 
cortex of AD brains, the level of PKC and the in vitro 
phosphorylation of its 86 kDa substrate are decreased, 
and there is a translocation of PKC activity from the 
particulate pool to the soluble cytosolic pool [166]. 
A possible function of PKC is the regulation of 
protein tyrosine phosphorylation [167,168]. The protein 
tyrosine kinase activity in the particulate fraction of 
frontal cortex appeared to decrease two-fold, whereas 
cytosolic protein tyrosine kinase activity was not al- 
fected in AD brains compared to control brains [169]. 
However, the amount of two (55 and 60 kDa) phospho- 
tyrosine immunoreactive polypeptides appeared to be 
increased in the frontal cortex and hippocampus of AD 
brains [169]. Because tyrosine kinase activity probably 
regulates PI 3-kinase activity, these findings could be 
directly related to the decreased PI kinasc activity in 
AD brain cortex as proposed by Jolles et al. [148] and 
Bothmer et al. [150]. 
E. The cytoskeleton and Alzheimer's disease: neurofibril- 
lary tangles 
As we have seen above (section II.C), the D-3 phos- 
phorylated phosphoinositides are involved in growth 
factor signalling and in the regulation of cytoskeleton 
turnover. A prominent feature in AD brains is the 
abnormal accumulation of markedly insoluble filamen- 
tous material within neuronal cell bodies and neurites 
[170]. These neurofibrillary tangles are found in several 
neurodegenerative diseases besides AD, such as post- 
encephalitic Parkinson's disease, Guam Parkinsonism 
dementia complex, dementia pugulistica, and Down's 
syndrome [116]. Neurofibrillary tangles are widely dis- 
tributed in AD brains, especially in the temporal and 
frontal cortices, hippocampus, some parts of the brain- 
stem and hypothalamus. Microscopically, they appear 
as bundles of paired helical filaments of which a micro- 
tubule-associated protein, called tau, is an important 
constituent [171-173]. Under normal conditions, tau 
acts as a promotor and stabilizer of tubule polymeriza- 
tion [174]. It has been suggested that tau is abnormally 
phosphorylated in paired helical filaments [171, 
175,176], a notion that is supported by the fact that the 
monoclonal antibody for normal tau recognizes tau in 
paired helical filaments only after treatment with alka- 
line phosphatase [173,177,178]. A68 protein in AD 
appears to be composed of several tau isoforms in a 
phosphorylated state which affects their elec- 
trophoretic mobility [179]. This abnormal phosphoryla- 
tion of tau has been demonstrated in AD and Down's 
syndrome [179,180]. Paired helical filament-tau ap- 
pears to contain 12 mol of phosphate per mol of tau, in 
contrast to normal tau from the brain of AD and 
control brain, which contains approximately 3 tool of 
phosphate per mol of tau [181]. Because phosphoryla- 
tion by cAMP-dependent protein kinase inhibits the 
degradation of tau by calpain, it is suggested that 
phosphorylation has a role in regulating the degrada- 
tion of tau. In addition, abnormal phosphorylation 
could result in a protease-resistant tau, which could 
contribute to the formation of paired helical filaments 
in AD [182]. Because of the important function of tau 
in promoting and stabilizing tubule polymerization, a 
disturbance in the phosphorylation of tau could possi- 
bly lead to destabilization of the cytoskeleton and 
ultimately to degeneration of axons and dendrites, 
which occurs in AD [183]. Among other proteins, only 
ubiquitin has been convincingly shown to be a part of 
the paired helical filaments [184], although there are 
indications that tropomyosine, a microfilament protein 
[185], neurofilament proteins [186] and MAP 2 and 5 
[187] are also constituents of paired helical filaments. 
The D-3 phosphorylated phosphoinositides seem to 
be involved in cytoskeletal reorganization because a 
lack of association of PI 3-kinase appears to correlate 
with a lack of actin reorganization and mitogenic sig- 
nalling [71]. It has been suggested that the key enzyme 
in the metabolism of these D-3 phosphorylated phos- 
phoinositides is specifically affected in AD [149,153]. 
Therefore, a change in the metabolism of these phos- 
phoinositides in AD could be closely related to the 
cytoskeletal changes in AD described above. 
V. Concluding remarks 
A disturbed signal transduction in the brain could 
underlie various age-related and Alzheimer's disease- 
related deficiencies. However, some of the age-related 
changes in the metabolism of phosphoinositides, as 
described in this review, could be explained by more 
general changes in the physical properties of mem- 
branes with age and in Alzheimer's disease. Thus in 
future research into age-related changes it will be 
important to correlate the findings with a biophysical 
parameter of the membrane, for example membrane 
fluidity. With respect to Alzheimer's disease, there is 
growing evidence that changes in the metabolism of 
phosphoinositides could be related to the characteristic 
cellular pathology of AD. Therefore it would be impor- 
tant to locate, by a better integration of the different 
areas of research, at what stage in the cascade of 
neurochemical events leading to the cellular pathology 
of Alzheimer's disease the changes in the phospho- 
inositide metabolism occur. Changes in the metabolism 
of brain phosphoinositides during aging and in 
Alzheimer's disease are potentially important because 
of the key role of phosphoinositides in several signal 
transduction pathways and in processes essential for 
cell functioning. A challenge for future research is to 
identify relationships between age-related changes in 
these pathways and processes, and the different bio- 
chemical and pathological changes that occur in aging 
and Alzheimer's disease. Considerable evidence sug- 
gests that the metabolism of phosphoinositides could 
be very important in this respect. 
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